Development of New Therapeutics Targeted to Induce Cell Death in Lung Cancer Stem Cells

Funding Type: 
Early Translational II
Grant Number: 
ICOC Funds Committed: 
Public Abstract: 
In the United States and in California, lung cancer is the leading cause of cancer death, killing more patients than breast, colon, and prostate cancers combined. Although tobacco smoke is the predominant risk factor for development of lung cancer, clinical observations suggest that the percentage of never smokers among lung cancer patients is steadily increasing, especially among women. Non-small cell lung cancer (NSCLC) is the predominant type of lung malignancy, representing about 85% of all cases. Although use of chemotherapy has helped to reduce NSCLC mortality, the five-year survival rate of patients with advanced disease remains at 15%, a rate that has been unchanged for over 20 years. It is clear that new therapies are urgently needed. The poor prognosis of NSCLC is often due to development of resistance to chemotherapy. Recent reports indicate that lung tumors contain subpopulations of cells, termed cancer stem cells, that account for less than 5% of the bulk tumor mass, but are largely responsible for drug resistance and consequent tumor recurrence. Importantly, the chemoresistance of cancer stem cells is reversed by parthenolide, a naturally-occurring compound reported to have strong antitumor activity in leukemia and prostate cancer. Anticancer effects of parthenolide appear due to its inhibition of tumor survival proteins that are markedly increased by administration of chemotherapy, with blockade of these survival proteins leading to reversal of chemoresistance. Although parthenolide selectively kills cancer stem cells, it has poor pharmacologic properties for use in the clinic. We hypothesize that use of parthenolide to selectively kill drug-resistant cancer stem cells in lung cancers may be a new strategy to eradicate NSCLC. To test this idea, new parthenolide analogues with improved bioavailability and antitumor action will be designed and synthesized in the chemistry laboratory. Then, drug-resistant cancer stem cells will be selected from bulk NSCLC cells, and reversal of chemoresistance by parthenolide analogues will be evaluated in the oncology laboratory. Promising anticancer compounds will then be assessed in human lung tumor xenograft models in vivo, with parallel studies to determine bioavailability and potential clinical utility. Further development of new targeted agents to kill drug-resistant cancer stem cells may significantly improve patient survival in the clinic. Thus, the proposed research will lead toward a development candidate based on cancer stem cells that will address an unmet medical need, namely the treatment and eradication of drug-resistant cancer stem cells in patients afflicted with lung cancer.
Statement of Benefit to California: 
The proposed research can have important benefits for the state of California and its citizens. According to recent reports on cancer incidence and mortality, about 17,910 individuals in California will be diagnosed with lung cancer this year and an estimated 12,750 Californians die from lung cancer annually. Although most lung cancers are a result of tobacco smoking, approximately 25% of lung cancer cases worldwide are estimated to be not attributable to tobacco use, accounting for over 300,000 deaths worldwide each year. In newly diagnosed non-small cell lung cancer, the predominant type of lung cancer, clinical observations suggest that 10% of men and 20% of women, with a much higher proportion among Asiatic women, have never smoked (never smokers). In general, current therapies for lung cancer have had only limited success, with a 5-year survival of about 15% for patients with advanced disease. Development of a new therapeutic targeting lung cancer stem cells that drive tumor progression can lead to more effective suppression of lung cancer and markedly advance patient survival in the clinic. Further, an orally-available anticancer agent may significantly reduce the high costs of medical care due to administration of intravenous chemotherapies and management of associated side-effects of these cytotoxic treatments.

© 2013 California Institute for Regenerative Medicine